Navigation Links
Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
Date:11/1/2011

PRINCETON, N.J., Nov. 1, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced the initiation of a Phase 3 program with the hepatitis C virus (HCV) nucleotide analog, PSI-7977. This pivotal program will evaluate a 12-week, all-oral, interferon-free regimen of PSI-7977 and ribavirin in patients with HCV, independent of viral genotype or their ability to take interferon therapy.

"After recent discussions with Health Authorities, we are excited to be initiating the first of a series of pivotal studies to explore an interferon-free regimen of PSI-7977 in broad populations of individuals with HCV," said Michael Rogers, Ph.D., Pharmasset's Chief Development Officer.

The first trial, FISSION, will enroll approximately 500 treatment-naive patients with HCV genotype 2 or 3, and will evaluate the safety and efficacy of a 12-week interferon-free regimen of PSI-7977 and ribavirin compared to 24 weeks of pegylated interferon and ribavirin. The primary endpoint of the study is sustained virologic response 12 weeks after the completion of treatment (SVR12).

Pharmasset plans to initiate a second 12-week duration, interferon-free Phase 3 trial, POSITRON, in early 2012. This trial will enroll approximately 225 patients with HCV genotype 2 or 3 who cannot take interferon.

In mid-2012, Pharmasset intends to initiate a third 12-week duration, interferon-free Phase 3 trial, NEUTRINO. This trial will enroll patients who cannot take interferon, and will include patients with HCV regardless of viral genotype, including those with HCV genotype 1. The final study design will be based on emerging data from ELECTRON and from PSI-7977 plus RBV-containing arms in the ongoing QUANTUM study.

"Based on encouraging results to date, we have selected an IFN-free regimen of PSI-7977/RBV for our registrational program," said Michelle Berrey, MD, MPH, Pharmasset's Chief
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Ore. , Aug. 29, 2014 /PRNewswire-iReach/ -- ... Accessory (Axilla) Strap for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today ... voluntary recall to address a potential issue with ... used for the Axilla application of the SAM ...
(Date:8/29/2014)... Calif. , Aug. 29, 2014 Thoratec ... in device-based mechanical circulatory support therapies to save, support ... participating in the 2014 Morgan Stanley Global Healthcare Conference ... Burbach , President and Chief Executive Officer, will provide ... Eastern Daylight Time (9:55 a.m., Pacific Daylight Time).   ...
(Date:8/29/2014)... 29, 2014 According to ... by Extraction type (SFE, Cold Pressed, Organic Solvent, & ... Pharmaceutical, Food Supplements, Fragrance, & Others) - Global Trends ... and segments the Amaranth Seed Oil Market with ... in terms of value. The Amaranth Seed Oil ...
Breaking Medicine Technology:SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4
... RALEIGH, N.C., Aug. 22, 2011 BioDelivery Sciences International, ... the commercial launch and availability of ONSOLIS (fentanyl buccal ...   (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) ONSOLIS is ... it will be marketed as BREAKYL) for the management ...
... SPRING, Md., Aug. 19, 2011 The U.S. Food ... treat Hodgkin lymphoma (HL) and a rare lymphoma known ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Lymphomas are cancers of ... combines an antibody and drug, allowing the antibody to ...
Cached Medicine Technology:BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada 2BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada 3FDA Approves Adcetris to Treat Two Types of Lymphoma 2FDA Approves Adcetris to Treat Two Types of Lymphoma 3
(Date:9/1/2014)... 1 September 2014: Permanent atrial fibrillation (AF) doubles the ... research in more than 6 000 patients presented at ... The findings suggest that a simple clinical assessment of ... estimate stroke risk. , Ischaemic stroke is the second ... a million deaths and many more disabled patients each ...
(Date:9/1/2014)... Bioinformatics refers to an interdisciplinary ... and genetic data. A major part of this ... tools to generate and process useful biological data. ... computation. While bioinformatics simply makes use of computers ... related concepts, biological computation refers to the subfield ...
(Date:9/1/2014)... September 01, 2014 Top10BestSEOHosting.com has ... many web host suppliers carefully, Top10BestSEOHosting.com is here ... the best web hosting suppliers in 2014. , ... clients with a top-of-the-line shared hosting plan. The ... easy-to-use platform that is affordable, accessible and powerful ...
(Date:9/1/2014)... Diego, CA (PRWEB) September 01, 2014 ... daily regarding all the latest information from the FDA ... , The US FDA announced on August 28, that ... recalled (Class I) as the device may ... the DePuy Synthes Craniomaxillofacial (CMF) Distraction System is an ...
(Date:9/1/2014)... 01, 2014 Psychogenic Non-epileptic Seizures (PNES), ... psychological disorder that can have devastating effects on those ... epileptic seizures however, they are not produced by electrical ... It is estimated that the numbers of persons ... multiple sclerosis. , Dr. Lorna Myers, Director ...
Breaking Medicine News(10 mins):Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2
... Tobacco Recognized Nationally-, WASHINGTON, May 20 Michelle ... Youth Advocate of the Year,by the Campaign for Tobacco-Free ... is being honored at a gala in the nation,s,capital ... grant winner,three other regional winners and a group winner., ...
... Mich., May 19 Patrick Hendry lost,his career, home, wife ... seven years in and out of the hospital, trying every ... trying,electro-convulsive therapy, similar to shock therapy., "That was a ... and lost," said Hendry. "It,s difficult to figure out what ...
... WASHINGTON, May 20 Auriel Rolle-Polk, 17, of,Tallahassee, FL ... the,Year by the Campaign for Tobacco-Free Kids for her ... at a gala in the nation,s capital,on May 20 ... regional winners and a group winner., Auriel, a ...
... (Amex: CPD ) announced that the Company ... year 2008 ended March 31, 2008,prior to the ... Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops,manufactures, markets and ... wholesalers, distributors,drugstore chains and managed care providers., ...
... Ischemic injury to the bowel is a well known disease ... findings. A sudden drop in the colonic blood supply is ... of macrovascular mesenteric vein rarely causes ischemia of the bowel. ... by obstruction of the mesenteric and splenic veins. , ...
... This release is available in Spanish . , , A ... out a study on the psychological process that triggers the craving ... bases to determine the brain mechanisms that activate this state and ... from the Department of Personality, Evaluation and Psychological Treatment ...
Cached Medicine News:Health News:Campaign for Tobacco-Free Kids Honors Michelle Mays of Rhinelander, WI As Youth Advocate of the Year 2Health News:Man who Lost Everything Comes to Detroit to Spread Message of Hope 2Health News:Campaign for Tobacco-Free Kids Honors Auriel Rolle-Polk of Tallahassee, FL As Youth Advocate of the Year 2Health News:Caraco Pharmaceutical Laboratories, Ltd. to Announce Fourth Quarter and Fiscal Year 2008 Results on May 29, 2008 2Health News:A research on 'craving' for tobacco establishes the bases for addiction control 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: